Avacta

Coris BioConcept is a medical device manufacturer specializing in rapid diagnostic kits for the detection of various human pathogens. Their product portfolio includes tests for respiratory, gastroenteric, blood-borne infections, as well as COVID-19, antibiotic resistance, bacteria, parasites, and viruses. The company develops, markets, and sells these products globally to provide comprehensive diagnostic solutions to its customers.

AffyXell Therapeutics, founded in January 2020 as a joint venture between Avacta and Daewoong, specializes in the development of innovative mesenchymal stem cell (MSC) therapies. The company focuses on creating next-generation cell and gene therapies aimed at treating inflammatory and autoimmune diseases, as well as preventing organ transplant rejection. By harnessing the potential of MSCs, which are recognized for their therapeutic capabilities, AffyXell aims to provide effective treatment options for various health conditions, thereby enhancing the quality of care delivered by healthcare professionals.

Aptuscan is a biotechnology company specializing in the development of engineered proteins tailored for pharmaceutical, biotechnology, and diagnostic sectors. The company is particularly focused on creating Scannins binding agents, which are utilized for the diagnosis and treatment of various diseases. Aptuscan's innovative products serve as essential resources for identifying binding agents that facilitate the development of therapeutics and diagnostics, as well as acting as research reagents for scientific inquiries.

ReactivLab Ltd., established in 2007 and headquartered in Glasgow, UK, specializes in animal diagnostics solutions. The company focuses on diagnosing and predicting illnesses by analyzing specific biomarker proteins, particularly acute phase proteins used as markers for infections, inflammation, neoplasia, and trauma signs. ReactivLab's technology enables early detection of subclinical diseases, facilitating timely veterinary interventions. As of March 3, 2010, the company operates as a subsidiary of Avacta Group Plc.

Curidium Medica identifies medicines and companion diagnostics for the treatment of central nervous system disorders.

Avacta Animal Health is an veterinary laboratory service provider and diagnostic tester to surgeons, laboratories, research & commercial organizations on animal allergies.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Oxford Medical Diagnostics develops laser-based technology for the analysis of gases. The company focuses on developing a platform for detecting minute quantities of markers in exhaled breath.